within Pharmacolibrary.Drugs.ATC.A;

model A02BC07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.52,
    Cl             = 4.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.028333333333333332,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02BC07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dexrabeprazole is the (S)-enantiomer of rabeprazole, a proton pump inhibitor (PPI) used to reduce gastric acid secretion. It is indicated for the treatment of gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), and other conditions related to excessive stomach acid. Dexrabeprazole is not widely approved or marketed independently but is primarily investigated as a potentially more potent and safer PPI compared to racemic rabeprazole.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for healthy adult subjects administered oral dexrabeprazole, derived by analogy to racemic rabeprazole due to lack of published clinical PK data specifically for dexrabeprazole.</p><h4>References</h4><ol><li><p>Zhang, HJ, et al., &amp; Wang, YQ (2020). Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. <i>Pharmacological research</i> 152 104606–None. DOI:<a href=&quot;https://doi.org/10.1016/j.phrs.2019.104606&quot;>10.1016/j.phrs.2019.104606</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31846760/&quot;>https://pubmed.ncbi.nlm.nih.gov/31846760</a></p></li><li><p>Fuhr, U, &amp; Jetter, A (2002). Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. <i>Die Pharmazie</i> 57(9) 595–601. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12369444/&quot;>https://pubmed.ncbi.nlm.nih.gov/12369444</a></p></li><li><p>Litalien, C, et al., &amp; Faure, C (2005). Pharmacokinetics of proton pump inhibitors in children. <i>Clinical pharmacokinetics</i> 44(5) 441–466. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544050-00001&quot;>10.2165/00003088-200544050-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15871633/&quot;>https://pubmed.ncbi.nlm.nih.gov/15871633</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02BC07;
